Clinical trials: Stage IV NSCLC
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC Stage IV, Brain Metastases
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis
The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis.
- Trial name
- NCT04745715
- Testing
- craniectomy
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Cheng-Kung University Hospital
NSCLC Stage IV, CRC
Donation of Post Mortem Tumor Tissues
DONUM is an observational prospective independent protocol for patients with advanced lung cancer, colorectal cancer or cancer of unknown primary, willing to donate their tumor tissue samples post mortem for biomedical research…
- Conditions
- NSCLC Stage IV, CRC, CUP
- Trial name
- DONUM (NCT03385980)
- Testing
- Proteomic analysis
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Niguarda Hospital
NSCLC Stage IV, NSCLC Stage IIIB
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
This study aims to understand the metastasis in advanced NSCLC through comparing genomic and transcriptomic patterns between the circulating tumor cells and metastatic tumor cells by single cell sequencing analysis.
- Trial name
- NCT04932343
- Testing
- cohort study
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
NSCLC Stage IV
T790M Mutation Testing in Blood by Different Methodologies
Three laboratories will participate in the study. Each laboratory will analyze the same samples by different methodologies according to the flow indicated in figure 1.
- Trial name
- NCT03363139
- Testing
- Tirosin Kinase Inhibitors
- Where
- 30 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Spanish Lung Cancer Group
NSCLC Stage IV, EGFR T790M-negative
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.
- Conditions
- NSCLC Stage IV, EGFR T790M-negative, Anlotinib, JS001
- Trial name
- NCT04116918
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Baodong Qin